Drug Profile
AMO 04
Alternative Names: AMO-04Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator AMO Pharma
- Developer AMO Pharma; Numedicus
- Class Neuroprotectants
- Mechanism of Action Glutamate modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rett syndrome
- No development reported Respiratory distress syndrome
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Respiratory-distress-syndrome in United Kingdom
- 16 Mar 2021 Phase II development in Rett syndrome is still ongoing (AMO Pharma pipeline, March 2021)
- 13 Jun 2018 AMO 04 receives Orphan Drug status for Rett syndrome in USA